Yung Zip Chemical Ind. Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 09, 2021
Share
Yung Zip Chemical Ind. Co., Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 137.054 million compared to TWD 120.160 million a year ago. Operating income was TWD 12.761 million compared to TWD 9.545 million a year ago. Net income was TWD 12.372 million compared to TWD 9.595 million a year ago. Basic earnings per share was TWD 0.29 compared to TWD 0.23 a year ago. For the half year, sales was TWD 244.421 million compared to TWD 224.649 million a year ago. Operating income was TWD 8.467 million compared to TWD 23.363 million a year ago. Net income was TWD 9.286 million compared to TWD 26.933 million a year ago. Basic earnings per share was TWD 0.22 compared to TWD 0.64 a year ago.
YUNG ZIP CHEMICAL IND. CO., LTD. is a Taiwan-based company principally engaged in the manufacturing and trading of pharmaceutical ingredient products. Its diclofenac sodium (DCS) is used for the treatment of rheumatoid arthritis, bursitis and inflammation. The acyclovir (ACV) is used for the treatment of herpes virus infections. The miconazole nitrate (MCN) is used for the treatment of yeast infection. The sodium starch glycolate (SSG) is used as disintegrant in pharmaceutical preparation. The Clonidine hydrochloride (CLD) is used for the treatment of hypertension. The Company mainly distributes its products in domestic market and overseas markets, including the United States of America (the USA), Thailand, Indonesia and the Philippines.
YUNG ZIP CHEMICAL IND. CO., LTD. 
